1. Home
  2. PED vs EQ Comparison

PED vs EQ Comparison

Compare PED & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

SELL

Current Price

$0.54

Market Cap

54.4M

Sector

Energy

ML Signal

SELL

EQ

Equillium Inc.

HOLD

Current Price

$1.20

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PED
EQ
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PED
EQ
Price
$0.54
$1.20
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$1.50
$1.00
AVG Volume (30 Days)
169.0K
510.3K
Earning Date
11-17-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
156.43
N/A
EPS
0.11
N/A
Revenue
$33,244,999.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$305.89
N/A
P/E Ratio
$5.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.27
52 Week High
$1.00
$2.35

Technical Indicators

Market Signals
Indicator
PED
EQ
Relative Strength Index (RSI) 44.20 56.95
Support Level $0.55 $0.84
Resistance Level $0.61 $1.44
Average True Range (ATR) 0.04 0.12
MACD 0.00 0.06
Stochastic Oscillator 49.92 60.99

Price Performance

Historical Comparison
PED
EQ

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: